Plain-English translation of NCT07496372 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment called HiCM-188, which uses stem cells grown in the laboratory and converted into heart muscle cells. The treatment is injected directly into the heart during bypass surgery to help repair damaged heart tissue. Researchers want to see if this combination approach works better than bypass surgery alone for people with severe heart failure.
Advanced heart failure causes significant disability and limits how much people can do in daily life. While surgery and medications help some patients, many still struggle with severe symptoms. This trial tests whether adding the new stem cell treatment could give patients' hearts a better chance to heal and function more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will either receive bypass surgery alone or bypass surgery combined with injections of the stem cell treatment into your heart. After surgery, you will take immunosuppressive medications to help your body accept the new cells. The research team will monitor your heart function, symptoms, and overall health for 12 months with follow-up visits and heart imaging tests.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
China